Urologix
This article was originally published in The Gray Sheet
Executive Summary
Expanded labeling approval for the Targis system includes a claim for treatment of the obstruction in the urethra caused by benign prostatic hyperplasia, the firm reports Aug. 7. No similar devices have been approved for this indication, the firm states. The system is currently approved for treatment BPH symptoms, such as frequent urination. Separately, the company reports revenues of $11.2 mil. for fiscal year 1998 ending June 30 compared to $5.5 mil. one year ago. Urologix books a larger net loss in FY 1998 ($15 mil.) versus its net loss in the year prior period ($8.2 mil.)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.